ACM
Aquilo Capital Management Portfolio holdings
AUM
$37.1M
This Quarter Return
+7.42%
1 Year Return
-36.49%
3 Year Return
+1.32%
5 Year Return
+39.69%
10 Year Return
–
AUM
$120M
AUM Growth
–
Cap. Flow
+$120M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
96.38%
Holding
14
New
13
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Merus
MRUS
|
$28.5M |
| 2 |
LOXO
Loxo Oncology, Inc
LOXO
|
$22M |
| 3 |
CytomX Therapeutics
CTMX
|
$14.9M |
| 4 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$14.1M |
| 5 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$10M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $28.5M | 23.48% |
+1,250,914
| New | +$28.5M |
|
|
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
| $22M | 18.14% |
+126,812
| New | +$22M |
|
|
3
CytomX Therapeutics
CTMX
$336M
| $14.9M | 12.25% |
+649,763
| New | +$14.9M |
|
|
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $14.1M | 11.59% |
+2,007,899
| New | +$14.1M |
|
|
PVLA
5
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $10M | 8.26% |
+1,975,098
| New | +$10M |
|
6
Fate Therapeutics
FATE
$120M
| $6.58M | 5.43% |
+580,229
| New | +$6.58M |
|
7
Spero Therapeutics
SPRO
$116M
| $6.11M | 5.04% |
+416,691
| New | +$6.11M |
|
8
Galapagos
GLPG
$2.07B
| $6.09M | 5.02% |
+66,050
| New | +$6.09M |
|
|
AUTL
9
Autolus Therapeutics
AUTL
$399M
| $4.02M | 3.31% |
+150,000
| New | +$4.02M |
|
|
CLLS
10
Cellectis
CLLS
$258M
| $3.36M | 2.77% |
+118,873
| New | +$3.36M |
|
11
Synlogic
SYBX
$17M
| $3.02M | 2.49% |
+306,794
| New | +$3.02M |
|
|
FPRX
12
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.03M | 0.85% |
+64,881
| New | +$1.03M |
|
|
MOR
13
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $303K | 0.25% |
+10,000
| New | +$303K |
|
14
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|